Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1181573-36-3

Post Buying Request

1181573-36-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1181573-36-3 Usage

General Description

The chemical compound "(1R,3S,4S)-2-Boc-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid Methyl ester" is a derivative of the bicyclic compound bicyclo[2.2.1]heptane. It is a methyl ester of a carboxylic acid, and the presence of a Boc (tert-butyloxycarbonyl) group on the nitrogen atom makes it a protected amino acid derivative. The compound has a stereochemistry with a 1R, 3S, and 4S configuration, indicating the positions of substituents on the bicyclic ring system. (1R,3S,4S)-2-Boc-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid Methyl ester can be used as a starting material or intermediate in organic synthesis for the preparation of complex molecules or pharmaceuticals. Its specific stereochemistry and functional groups make it suitable for use in asymmetric synthesis and the construction of chiral compounds.

Check Digit Verification of cas no

The CAS Registry Mumber 1181573-36-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,1,5,7 and 3 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1181573-36:
(9*1)+(8*1)+(7*8)+(6*1)+(5*5)+(4*7)+(3*3)+(2*3)+(1*6)=153
153 % 10 = 3
So 1181573-36-3 is a valid CAS Registry Number.

1181573-36-3Downstream Products

1181573-36-3Relevant articles and documents

Compound with nitrogen-containing bridge ring, spiro or fused ring structure and application thereof

-

Paragraph 0150-0152, (2020/08/12)

The invention discloses a compound with a nitrogen-containing bridge ring, spiro or fused ring structure and application of the compound. The compound has an obvious inhibition effect on the activityof protein kinase, can be used as a BTK inhibitor for preparing drugs for treating BTK-mediated diseases including, but not limited to, autoimmune diseases, malignant tumors and the like, and has a wide application prospect.

Preparation method of high-purity Ledipasvir intermediate

-

, (2017/02/24)

The invention discloses a preparation method of a high-purity Ledipasvir intermediate (1R, 3S and 4S)-N-t-butylcarbonyl-2-azabicyalo[2.2.1] heptane-3-carboxylic acid. According to the method, (1R, 3S and 4S)-N-t-butylcarbonyl-2-azabicyalo[2.2.1] heptane-3-carboxylate serves as an initial raw material, and the Ledipasvir intermediate is obtained through enzymatic hydrolysis. A test proves that the high-purity Ledipasvir intermediate is obtained and a feasible path is provided for reducing production cost and improving drug use safety. Meanwhile, the method has the advantages that operation is easy, environment friendliness is achieved, the yield is high, selectivity is high and cost is low; large-scale production can be achieved, and industrial application and popularization are facilitated.

Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

Link, John O.,Taylor, James G.,Xu, Lianhong,Mitchell, Michael,Guo, Hongyan,Liu, Hongtao,Kato, Darryl,Kirschberg, Thorsten,Sun, Jianyu,Squires, Neil,Parrish, Jay,Keller, Terry,Yang, Zheng-Yu,Yang, Chris,Matles, Mike,Wang, Yujin,Wang, Kelly,Cheng, Guofeng,Tian, Yang,Mogalian, Erik,Mondou, Elsa,Cornpropst, Melanie,Perry, Jason,Desai, Manoj C.

supporting information, p. 2033 - 2046 (2014/04/03)

A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was discovered. Optimization of antiviral potency and pharmacokinetics led to the identification of 39 (ledipasvir, GS-5885). Compound 39 (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. 39 has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1181573-36-3